Business
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients
iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the World Transplant CongressNational Principal
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined score","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Data show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patients","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"iMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"iMDx will be exhibiting at Booth #324 at the World Transplant Congress","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"National Principal Investigator and Key Opinion Leader call Friday, August 15th at 4 p.m. ET to discuss GraftAssureTM - branded family of assays","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":626,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., July 30, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced two favorable oral abstracts, including one late-breaking, that will be presented at the World Transplant Congress from August 2 to 6, in San Francisco.","length":276,"tagName":"p"},{"type":"text","content":"The late-breaking study validated iMDx’s novel approach to quantification of donor-derived cell-free DNA, or dd-cfDNA, an established molecular biomarker of transplant rejection. The study analyzed 403 samples from five clinical cohorts by combining both relative dd-cfDNA quantification (expressed as a percentage) and absolute quantities (copies/mL plasma) of donor-specific DNA targets into a single score. The results show an unpre...